Dawson James analyst Jason Kolbert maintained a Hold rating on Soligenix (SNGX – Research Report) on July 26. The company’s shares closed last Friday at $0.88.
According to TipRanks.com, Kolbert is a 1-star analyst with an average return of -2.0% and a 34.7% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals.
Soligenix has an analyst consensus of Hold.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $1.23 and a one-year low of $0.38. Currently, Soligenix has an average volume of 217.8K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SNGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
Read More on SNGX:
- Dawson James Sticks to Its Hold Rating for Adamis Pharma (ADMP)
- PBF Energy (PBF) Gets a Buy Rating from Mizuho Securities
- Morgan Stanley Keeps Their Buy Rating on Audinate Group Ltd. (AUDGF)
- Evercore Analyst David Palmer: DPZ and MCD Are Top Restaurant Picks
- UBS Maintains a Sell Rating on Kogan.com Ltd. (KGGNF)
